Otsuka to stops development of Alzheimer’s candidate AVP-786
Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) and its US subsidiary have decided to terminate the development of the novel compound AVP-786, which was being studied as a potential treatment for patients with agitation associated with dementia due to Alzheimer's disease.
Otsuka initiated Phase III trials for AVP-786. In the top-line results of the Phase III trial NCT03393520 that Otsuka announced in February this year, no statistically significant difference was observed between AVP-786 and placebo in the primary endpoint--average change from baseline to week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) total score. The drug also failed in a previous Phase III trial for the treatment of moderate-to-severe agitation in patients with Alzheimer's dementia.
Otsuka now says that, after a detailed analysis of results from the completed trial, it has decided to terminate the development of this drug candidate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze